Patent

InSpan granted patent protection by the US Patent Office for its unique interspinous technique and instruments designed for treating spinal stenosis and fusion in the ASC

Retrieved on: 
Wednesday, March 22, 2023
Spinal fusion, ASC, SAFE, IPD, United States patent law, Spinal stenosis, Journal, Patent, Patient, Investment, FIRST, CFO, JSS, Decompression, FDA, Pharmaceutical industry, Medical device

MALDEN, Mass., March 21, 2023 /PRNewswire-PRWeb/ -- NANISX LLC is the parent company for InSpan LLC and is grateful that the US Patent Office (USPTO) has allowed for issuance as a patent to protect the unique InSpan approach. This is yet another momentous achievement and a leap forward for patients with spine pain, especially over 55 years old, who want a safe and less invasive surgery with quick recovery in an outpatient ambulatory surgery center (ASC).

Key Points: 
  • On March 8th, 2023, the US Patent Office allowed for issuance as a patent of the InSpan technique and unique instruments establishes InSpan as a proven and validated leading technology for interspinous-interlaminar fixation ideally suited for outpatient spine surgery to treat spinal stenosis and for spinal fusion.
  • MALDEN, Mass., March 21, 2023 /PRNewswire-PRWeb/ -- NANISX LLC is the parent company for InSpan LLC and is grateful that the US Patent Office (USPTO) has allowed for issuance as a patent to protect the unique InSpan approach.
  • InSpan has been FDA-cleared since 2010 and thousands have been implanted safely with excellent clinical outcomes and no adverse device related events.
  • Visit InSpan to request help in locating a doctor near you that performs InSpan surgeries.

Crusoe Energy Systems, Alkane Midstream Agree to Resolve Lawsuit

Retrieved on: 
Tuesday, March 21, 2023
Environment, Technology, Other Energy, Oil, Gas, Sustainability, Green Technology, Energy, Mining, Minerals, Hardware, Natural Resources, Permian, Patent, Natural gas, Alkane, Crusoe

Crusoe Energy Systems LLC (Crusoe) and Alkane Midstream LLC (Alkane) announced today that they have agreed to resolve a lawsuit related to patent infringement.

Key Points: 
  • Crusoe Energy Systems LLC (Crusoe) and Alkane Midstream LLC (Alkane) announced today that they have agreed to resolve a lawsuit related to patent infringement.
  • Both parties have agreed to dismiss the lawsuit and enter into a mutually beneficial license agreement.
  • Denver-based Crusoe builds and operates Digital Flare Mitigation systems, a technology that converts otherwise stranded and flaring natural gas into on-site computation to reduce waste and emissions.
  • The initial lawsuit was filed in August 2022 with the Denver Division of Colorado’s Federal Court.

Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 21, 2023
ER, Medicaid, SG, TD, AMCP, Tardive dyskinesia, Marketing, United States Patent and Trademark Office, Prescription, Evoke, Gastroenterology, Research, Holocene, DDW, Traction, Gastroparesis, Patent, Patient, Academy of Managed Care Pharmacy, Risk, Physician, Metoclopramide, FDA, Pharmaceutical industry, Nursing, Cryptocurrency

SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2022, and recent corporate developments.

Key Points: 
  • “In the fourth quarter of 2022, our net product sales from prescriptions decreased slightly to $796,000, from $832,000 in the third quarter of 2022, resulting from increased prescription sales to uninsured or under-insured patients.
  • Prescription fills increased 8% in the fourth quarter 2022 compared to the third quarter while full year prescription fills increased 178%.
  • For the fourth quarter of 2022 selling, general and administrative (SG&A) expenses were approximately $2.3 million compared with $1.7 million for the fourth quarter of 2021.
  • Total operating expenses for the fourth quarter of 2022 were approximately $2.3 million compared with $1.8 million for the same period of 2021.

Tech+IP Announces New BlackBerry Patent Deal to Sell Substantially All of Its Non-Core Patents and Applications

Retrieved on: 
Tuesday, March 21, 2023
BlackBerry Limited, Shearman & Sterling, IP, Oliver Cromwell, BlackBerry, Patent, Sullivan & Cromwell, Investment, TSX, BB, NYSE, Mobile phone, Cryptocurrency

"While those in the industry know this process has been running for some time, stated Ed Fish, co-Founder and Managing Director of Tech+IP Advisory, what is noteworthy is the quality of these patents -- important to many markets but non-core to BlackBerry's business – and the robust, long-term process we spearheaded with the internal BlackBerry team that was able to withstand the serial shocks of the war in Ukraine, post-COVID disruptions, inflation, and a significant uncertainty regarding liquidity in the markets capped by prominent U.S. and global bank failures."

Key Points: 
  • https://www.prnewswire.com/news-releases/blackberry-announces-new-patent...
    The deal includes close to 32,000 patents and applications relating primarily to mobile devices, messaging and wireless networking and excludes patents and applications that are necessary to support BlackBerry's current core business operations and a set of non-core patent families relating to mobile devices, primarily standards essential patents.
  • The newly announced deal needs to obtain Canadian and U.S. regulatory approvals.
  • The team at Tech+IP leading the firm's advisory role for BlackBerry also included Bojan Marijanovic, Adi Hrustanovic, Chuck Fish and numerous others.
  • Sullivan & Cromwell served as legal counsel for BlackBerry, and Shearman Sterling for Tech+IP' in its first fairness opinion portion of the work.

CGT Staffing Partners with Law Firms to Build Comprehensive and Productive Teams

Retrieved on: 
Tuesday, March 21, 2023
Welge, United States Patent and Trademark Office, COVID-19, Eye, Patent, CGT, Marketing, Bankruptcy, Management

Law offices are hiring purposefully with an eye on expansion, reevaluating their billing practices, and adapting to digitized work and recordkeeping practices.

Key Points: 
  • Law offices are hiring purposefully with an eye on expansion, reevaluating their billing practices, and adapting to digitized work and recordkeeping practices.
  • CGT Staffing has proven itself as a key partner to a number of expanding firms," said Alaina Santucci, Senior Account Manager.
  • roles – a long-time niche specialty of CGT Staffing – as organizations reimagine and expand their cybersecurity, cloud services, and business intelligence teams.
  • Intellectual property law is a rapidly expanding office within most firms, increasingly seeking candidates with viable Patent and Trademark (USPTO) experience.

Cigent Patents Technology that Ensures Complete Erasure of Storage Drives and Endpoint Devices

Retrieved on: 
Tuesday, March 21, 2023
Citadel, Organic, Intellectual property, GSA, SLED, EOL, ATA, TD, CCPA, Research, Government, SSD, Seagate, Patent, NSA, NCPA, Risk, TD Synnex, FIPS, GDPR, Barracuda, Solid-state drive, HIPAA, PII, Computer data storage, Engineering

FORT MYERS, Fla., March 21, 2023 /PRNewswire-PRWeb/ -- Cigent® Technology, Inc., the leader in embedded cybersecurity in storage devices, today announced that they have been assigned a patent (11581048) developed by Tony Fessel, VP of Engineering, Fort Myers, FL, for "method and system for validating erasure status of data blocks."

Key Points: 
  • Storage devices provide a response indicating the erase command was completed successfully, in theory, wiping all data.
  • To address these gaps, Cigent's patented technology is now included in its Verified Device Erasure, firmware-based verification capability.
  • Verified Device Erasure scans the complete Storage SSD to verify the type of blocks and whether data has been erased.
  • "Cigent Verified Device Erasure is the only reliable method to verify that an SSD has truly been erased and can be safely repurposed," said Tom Ricoy, CRO at Cigent.

Normalyze Granted First Patent for Data Security Posture Management (DSPM)

Retrieved on: 
Tuesday, March 21, 2023
Cloud, Patent, Platform as a service, Infrastructure as a service, Information security, GRC, CMDB, Microsoft, CSPM, Information, SAN, Google Cloud, Snowflake, Sigma, Azure, AWS, Video game

SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Normalyze, a pioneering provider of cloud data security solutions, was granted the most fundamental patent to date for Data Security Posture Management (DSPM) by the U.S. Patent and Trademark Office. The patent addresses cloud data attack path detection based on security posture of the cloud environment and resource network path tracing. This patent is foundational for an emerging data-first approach to secure cloud-resident sensitive data and its implications will help to innovate the enterprise cybersecurity market at large.

Key Points: 
  • SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Normalyze , a pioneering provider of cloud data security solutions, was granted the most fundamental patent to date for Data Security Posture Management (DSPM) by the U.S. Patent and Trademark Office.
  • The patent addresses cloud data attack path detection based on security posture of the cloud environment and resource network path tracing.
  • Patent #11,575,696 describes how an accurate measure of cloud security posture enables the Normalyze DSPM platform to automatically trace network paths at scale between cloud-resident sensitive data and all points of access to determine attack paths.
  • The Normalyze patent details how its technology, via integration, improves systems and methods of separate siloed tools such as cloud security posture management (CSPM), cloud infrastructure entitlement management (CIEM), cloud-native application protection platform (CNAPP), and/or cloud-native configuration management databases (CMDB).

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Retrieved on: 
Tuesday, March 21, 2023
Notice of Intent to Revoke, Pancreatic cancer, Patent, European Patent Office, United States Patent and Trademark Office, Trademark, Investigational New Drug, Cancer, European Patent Convention, Orphan, Therapy, IND, Pharmaceutical industry

The patent protects composition of matter for QN-302 and back-up compounds, with exclusivity to the Company into 2040.

Key Points: 
  • The patent protects composition of matter for QN-302 and back-up compounds, with exclusivity to the Company into 2040.
  • Concurrently, the Company has received Notice of Intent from the European Patent Office to grant a similar patent in the E.U.
  • “A key pillar in the development of therapeutic drugs is a company’s intellectual property portfolio,” commented Michael Poirier, CEO and Chairman of Qualigen.
  • “This particular U.S. patent is of paramount importance to us, as it protects the formulation itself and is integral to our development of QN-302.

NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra

Retrieved on: 
Tuesday, March 21, 2023
Professional Services, Patent Law, Medical Devices, Health, Health Technology, General Health, Patent, Catheter-associated urinary tract infection, United States Patent and Trademark Office, Patent application, SAWS, JN-International Medical Corporation, Patient, Ultra, CAUTI, Medical imaging

NanoVibronix, Inc ., (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (“SAW”) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (“USPTO”) entitled “Multiple Frequency Surface Acoustic Waves for Internal Medical Device” (the "Patent Application") related to its UroShield.

Key Points: 
  • NanoVibronix, Inc ., (NASDAQ: NAOV) (the “Company”), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (“SAW”) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (“USPTO”) entitled “Multiple Frequency Surface Acoustic Waves for Internal Medical Device” (the "Patent Application") related to its UroShield.
  • The Patent Application covers a recently developed enhancement to the UroShield product, UroShield “Ultra”, which incorporates improvements to the Company’s original UroShield.
  • The next generation UroShield Ultra includes modified housing that is designed to improve catheter coupling and incorporates multiple actuators that work in sequence to discourage bacterial docking by delivering SAWs at multiple frequencies directly to indwelling catheters.
  • UroShield has been proven to be instrumental in improving outcomes for hospital patients suffering from CAUTI.

Robotics Provider Exotec Accelerates North American Business Momentum in 2023 with a Major Manufacturing Milestone, Continuous Innovation, and Rapidly Growing Customer Base

Retrieved on: 
Tuesday, March 21, 2023
Moon, Skypath, E-commerce, Organization, Growth, Business development, Robotics, Fortune 500, Patent, Automation, Heavy equipment

ATLANTA, March 21, 2023 /PRNewswire/ -- Today, Exotec, a global warehouse robotics provider, announced its continued rapid growth in North America as the company continues its global expansion. The business momentum is driven by the growing demand for warehouse automation. 

Key Points: 
  • ATLANTA, March 21, 2023 /PRNewswire/ -- Today, Exotec , a global warehouse robotics provider, announced its continued rapid growth in North America as the company continues its global expansion.
  • "We continue to see a strong demand for scalable and proven warehouse robotic solutions," says Exotec CEO and Co-founder Romain Moulin.
  • The achievement is a testament to Exotec's rapidly growing manufacturing capabilities and the growing demand for the company's products.
  • To date, Exotec employs around 55 professionals in North America and aims to double the headcount by 2024.